Westmore · UDRP DecisionBuyandrogel.com
The Panel ordered the transfer of <buyandrogel.com> to Besins Healthcare Luxembourg Sarl. It found the domain confusingly similar to the Complainant’s longstanding ANDROGEL trademarks, found no rights or legitimate interests because the Complainant’s prima facie case was unrebutted, and found bad-faith registration and use based on the distinctive coined mark, the Respondent’s actual or constructive awareness of it, the domain’s composition, and passive holding through an “under construction” website.
The timeline behind buyandrogel.com
Registration, the decision and the archived record of what this domain actually displayed — from public RDAP and the Internet Archive.
Westmore reconstructs the full history behind buyandrogel.com — from public RDAP and the Internet Archive — as part of UDRP Intelligence:
This decision illustrates application of the passive-holding doctrine to a newly registered domain incorporating an entire coined pharmaceutical mark. The absence of active website content did not prevent transfer where the trademark substantially predated the domain, remained clearly recognizable, was found inherently distinctive, and the Respondent offered no competing explanation or evidence of legitimate use.
Result of record. The panel's reasoning and decisive facts behind each element are in the Intelligence dossier below.
ARBITRATION AN D MEDIATION CENTER ADMINISTRATIVE PANEL DECISION Besins Healthcare Luxembourg Sarl v. Daisha Thomas Case No. D2026-3027 1. The Parties The Complainant is Besins Healthcare Luxembourg Sarl, Luxembourg, represented by Nameshield, France. The Respondent is Daisha Thomas, United States of America (“United States”). 2. The Domain Name and Registrar The disputed domain name <buyandrogel.com> is registered with Squarespace Domains LLC (the “Reg istrar”). 3. Procedural History The Complaint was filed with the WIPO Arbitration and Mediation Center (the “Center”) on July 9, 2026. On July 9, 2026, the Center transmitted by email to the Registrar a request for registrar verification in connection with the disputed domain name. On July 10, 2026, the Registrar transmitted by email to the Center its verif ication response disclosing registrant and contact inf ormation f or the disputed domain name which dif f ered f rom the named Respondent (REDACTED FOR PRIVACY) and contact inf ormation in the Complaint. The Center sent an email communication to the Complainant on July 10, 2026, providing the registrant and contact information disclosed by the Registrar, and inviting the Complainant to submit an amendment to the Complaint. The Complainant f iled an amended Complaint on July 13, 2026. The Center verif ied that the Complaint together with the amended Complaint satisf ied the f ormal requirements of the Uniform Domain Name Dispute Resolution Policy (the “Policy” or “UDRP”), the Rules f or Unif orm Domain Name Dispute Resolution Policy (the “Rules”), and the WIPO Supplemental Rules f or Unif orm Domain Name Dispute Resolution Policy (the “Supplemental Rules”). In accordance with the Rules, paragraphs 2 and 4, the Center f ormally notif ied the Respondent of the Complaint, and the proceedings commenced on July 16, 2026. In accordance with the Rules, paragraph 5, the due date for Response was August 5, 2026. The Respondent did not submit any response. Accordingly, the Center notif ied the Respondent’s def ault on August 18, 2026. page 2 The Center appointed Eric Macramalla as the sole panelist in this matter on August 20, 2026. The Panel f inds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7. 4. Factual Background Founded in 1885, the Complainant is a pharmaceutical company specialized in obstetrics, gynecology, urology and andrology. It offers novel therapies for gynecology and andrology. The ANDROGEL product is a replacement therapy f or treating testosterone def iciency. The product is indicated in adults as testosterone replacement therapy f or male hypogonadism. The Complainant is the owner of numerous trademark registrations comprised of, or containing, ANDROGEL (the “ANDROGEL Trademarks”), including the f ollowing: (a) ANDROGEL, International Registration No. 475204 f iled f or use in association with Class 5, and registered since March 3, 1983. (b ) ANDROGEL, International Registration No. 797636 filed f or use in association with Classes 5 and 38, and registered since February 6, 2003. The Complainant owns several domain names comprised of the ANDROGEL trademark, including <androgel.com>, which was registered on October 5, 1999. The disputed domain name was registered on July 4, 2026. The disputed domain name has been made to resolve to a website which is indicated as being “under construction”. 5. Parties’ Contentions A. Complainant The Complainant contends that it has satisfied each of the elements required under the Policy f or a transf er of the disputed domain name. The Complainant has alleged that the disputed domain name is conf usingly similar to the ANDROGEL Trademarks in which it has rights. The Respondent has incorporated the whole of the ANDROGEL trademark in the disputed domain name. The Respondent has no rights or legitimate interests in the disputed domain name as contemplated by paragraph 4(c) of the Policy. The Complainant has not authorized the Respondent to use ANDROGEL Trademarks and is not otherwise connected to the Respondent. The Respondent’s activities do not constitute a bona fide offering of goods or services, the Respondent is not commonly known by the disputed domain name, and that the Respondent is not making any legitimate noncommercial or f air use of the domain name. The disputed domain name was registered and is used in bad f aith as per paragraph 4(a)(iii). The Respondent’s passive holding of the disputed domain name also supports a finding of bad faith as does the Respondent’s likely knowledge of the ANDROGEL Trademarks. page 3 B. Respondent The Respondent did not reply to the Complainant’s contentions. 6. Discussion and Findings As per paragraph 4(a) of the Policy, to succeed a complainant must establish the f ollowing: (i) the disputed domain name is identical or confusingly similar to a trademark or service mark in which the complainant has rights; (ii) the respondent has no rights or legitimate interests in respect of the disputed domain name; and (iii) the disputed domain name was registered and is being used in bad f aith. These elements are discussed in turn below. In considering these elements, paragraph 15(a) of the Rules provides that the Panel shall decide the Complaint on the basis of statements and documents submitted and in accordance with the Policy, the Rules and any other rules or principles of law that the Panel deems applicable. A. Identical or Confusingly Similar It is well accepted that the f irst element f unctions primarily as a standing requirement. The standing (or threshold) test for confusing similarity involves a reasoned but relatively straightforward comparison between the Complainant’s trademark and the disputed domain name. WIPO Overview of WIPO Panel Views on Select UDRP Questions (WIPO Overview 3.1, section 1.7). The generic Top-Level Domain is typically disregarded in determining the issue of conf using similarity. WIPO Overview 3.1, section 1.11.1. The Complainant has established rights in respect of a trademark f or the purposes of the Policy. WIPO Overview 3.1, section 1.2.1. The Complainant has established longstanding rights in the ANDROGEL Trademarks in numerous jurisdictions worldwide. Furthermore, the Panel finds the mark is recognizable within the disputed domain name as contains the ANDROGEL trademark. Under the circumstances, the Panel f inds conf using similarity. The Panel f inds the f irst element of the Policy has been established. B. Rights or Legitimate Interests Paragraph 4(c) of the Policy provides a list of circumstances in which the Respondent may demonstrate rights or legitimate interests in a disputed domain name. Although the overall burden of proof in UDRP proceedings is on the complainant, panels have recognized that proving that a respondent lacks rights or legitimate interests in a domain name may result in the dif f icult task of “proving a negative”, requiring information that is often primarily within the knowledge or control of the respondent. As such, where a complainant makes out a prima facie case that the respondent lacks rights or legitimate interests, the burden of production on this element shifts to the respondent to come f orward with relevant evidence demonstrating rights or legitimate interests in the domain name (although the burden of proof always remains on the complainant). If the respondent f ails to come f orward with such relevant evidence, the complainant is deemed to have satisf ied the second element. WIPO Overview 3.1, section 2.1. page 4 Having reviewed the available record, the Panel finds, on a balance of probabilities, that the Complainant has established a prima facie case that the Respondent lacks rights or legitimate interests in the disputed domain name. The Respondent has not rebutted the Complainant’s prima facie showing and has not come f orward with any relevant evidence demonstrating rights or legitimate interests in the disputed domain name such as those enumerated in the Policy or otherwise. The Complainant has not authorized, licensed, or otherwise permitted, the Respondent to use the ANDROGEL Trademarks in any manner, including as part of a domain name. There is also no evidence that the Respondent is commonly known by the disputed domain name. There is also no basis to conclude that the Respondent is making legitimate noncommercial or fair use of the disputed domain name, without intent f or commercial gain to misleadingly divert consumers or to tarnish the trademark or service mark at issue. There is also no evidence that the Respondent has used, or made demonstrable preparations to use, the disputed domain name in connection with a bona f ide of f ering of goods or services. The Panel f inds the second element of the Policy has been established. C. Registered and Used in Bad Faith The Panel notes that, f or the purposes of paragraph 4(a)(iii) of the Policy, paragraph 4(b) of the Policy establishes circumstances, in particular, but without limitation, that, if found by the Panel to be present, shall be evidence of the registration and use of a domain name in bad f aith. While paragraph 4(b) of the Policy sets out a list of non-exhaustive circumstances that may indicate that a domain name was registered and used in bad faith, other circumstances may also be relevant in assessing whether a respondent’s registration and use of a domain name is in bad faith. WIPO Overview 3.1, section 3.2.1. The ANDROGEL trademark is a coined term, is inherently distinctive, has been in use f or decades, and is the subject of many trademark registrations worldwide. The Panel theref ore concludes that the Respondent knew, or should have known, that the disputed domain name was likely to be confused with the ANDROGEL Trad emarks. The Panel f inds that the disputed domain name was registered in bad f aith. Panels have f ound that the non-use of a domain name (including a blank or “coming soon” page) would not by itself prevent a finding of bad faith under the doctrine of passive holding. To the contrary, in looking at the totality of circumstances in each case, panels have f ound that the registration and non-use of a domain name can still constitute bad f aith f or purposes of the Policy. WIPO Overview 3.1, section 3.3. In the present case, the disputed domain name, which was registered years after the Complainant registered its trademark, is confusingly similar to the ANDROGEL Trademarks and, if ever put to use, is likely to cause conf usion among Internet users as to the source, affiliation, or sponsorship of the disputed domain name. Having considered the reputation or distinctiveness of the Complainant’s trademark, and the composition of the disputed domain name, the Panel finds that the passive holding of the disputed domain name does not prevent a f inding of bad f aith under the circumstances of this case. Theref ore, having reviewed the record, the Panel finds the registration and use of the disputed domain name constitutes bad f aith under the Policy. The Panel f inds that the Complainant has established the third element of the Policy. page 5 7. Decision For the f oregoing reasons, in accordance with paragraph 4(i) of the Policy and 15 of the Rules, the Panel orders that the disputed domain name <buyandrogel.com> be transf erred to the Complainant. /Eric Macramalla/ Eric Macramalla Sole Panelist Date: September 2, 2026
Source of record: WIPO . Reproduced for research; WIPO is the authoritative source.
What Westmore sees around buyandrogel.com
The decision is only the record. Westmore connects it to the cases, authorities, panelists, parties and domain evidence surrounding it.

A short, grounded explanation drawn only from this decision's record — not legal advice or a prediction.
Grounded in the Westmore record for this decision. Research/informational only — not legal advice or a prediction of any outcome.
The decision is only the beginning.
You've seen what happened. Now discover the deeper intelligence behind the case, the panelist, the parties and the authorities that matter.
Go beyond the public record: see how this case has been cited, find comparable decisions, analyze the panelist and apply the relevant authorities to your Matter.
Westmore Professional · $395/month
Research with UDRP IntelligenceWestmore AI drafts an attorney-review-ready UDRP response from your facts, grounded in the exact panel and closest precedent.
$895 one-time per matter · no subscription required. Self-help drafting aid — not legal advice.
Build your responseWestmore UDRP records draw on WIPO-indexed decisions and are provided for research and informational purposes only. Not legal advice, a clearance opinion, or a prediction of any outcome.